These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31568878)

  • 1. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
    Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
    Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
    Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum
    Liu W; Ma Y; He Y; Liu Y; Guo Z; He J; Han X; Hu Y; Li M; Jiang R; Wang S
    J Med Chem; 2024 Jun; 67(11):9645-9661. PubMed ID: 38776419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and characterization of a PAMAM-OH derivative containing an acid-labile β-thiopropionate bond for gene delivery.
    Chen K; Chen Q; Wang K; Zhu J; Li W; Li W; Qiu L; Guan G; Qiao M; Zhao X; Hu H; Chen D
    Int J Pharm; 2016 Jul; 509(1-2):314-327. PubMed ID: 27260132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
    Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
    Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
    Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
    Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
    Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.
    Berberich A; Kessler T; Thomé CM; Pusch S; Hielscher T; Sahm F; Oezen I; Schmitt LM; Ciprut S; Hucke N; Ruebmann P; Fischer M; Lemke D; Breckwoldt MO; von Deimling A; Bendszus M; Platten M; Wick W
    Clin Cancer Res; 2019 Jan; 25(1):253-265. PubMed ID: 30274984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
    Phelps D; Bondra K; Seum S; Chronowski C; Leasure J; Kurmasheva RT; Middleton S; Wang D; Mo X; Houghton PJ
    Pediatr Blood Cancer; 2015 Aug; 62(8):1345-52. PubMed ID: 25832557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.
    Zhou Z; Zalutsky MR; Chitneni SK
    Mol Pharm; 2021 Oct; 18(10):3871-3881. PubMed ID: 34523337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
    Cui Y; Zhou J; Rong F
    Biochem Biophys Res Commun; 2020 Dec; 533(4):665-671. PubMed ID: 33051060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity.
    Abed A; Greene MK; Alsa'd AA; Lees A; Hindley A; Longley DB; McDade SS; Scott CJ
    Mol Pharm; 2024 Mar; 21(3):1246-1255. PubMed ID: 38334409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.